link to RWJMS home page
Banner Image Here

Research

Publications

Saraiya B, Gounder M, Dutta J, Saleem A, Collazo C, Zimmerman L, Nazar A, Gharibo M, Schaar D, Lin Y, Aisner J, Strair RK, Rubin EH: Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anticancer Drugs, 2008; 19:411-420.

Medina DJ, Gharibo M, Savage P, Cohler A, Kuriyan M, Balsara B, Anand M,

Schaar D, Krimmel T, Saggiomo K, Manago J, Talty L, Dudek L, Grospe S, Rubin A, Strair RK. A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leuk Res. 32(12):1842-1848, 2008.

Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin HC, Lin Y,

Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. Nuclear factor- Kappa B modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res.15;14(22):7564-7568, 2008.

Lu-Yao GL, Moore DF, Shih W, Lin Y, DiPaola RS, Albertsen P, SL Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer.  JAMA 2008; 300:173–181 PMID 2645653.

Parekh N, Lin Y, Marcella S, Kant AK, Lu-Yao GL. Associations of lifestyle and physiological factors on prostate‑specific antigen concentrations from NHANES(2001‑2004). Cancer Epidemiology Biomarkers and Prevention 2008; 17(9): 2467-72.

Meissner HI, Tiro JA, Haggstrom D, Lu-Yao G, Breen N.  Does Patient Health and Hysterectomy Status Influence Cervical Cancer Screening in Older Women?  J Gen Intern Med 2008; 23(11): 1822-1828.

Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Corkery EW, Barry MJ.

Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: Fifteen-year follow-up.  J Gen Intern Med 2008; 23(11): 1809-1814.

Hudson S, Ohman-Strickland P, Ferrante J, Lu-Yao GL, Crabtree B.  Prostate-specific antigen testing among the elderly in community-based family medicine practices.  Journal of the American Board of Family Medicine 2009; 22:257-65.

Goodin S.  Ixabepilone:  a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer.  Am J Health Sys Pharm 2008;65:2017-2026.

Medina PJ, Goodin S.  Lapatinib:  A review of the dual inhibitor of epidermal growth factor receptor tyrosine kinase.  Clinical Therapeutics 2008 August, 30 (8):1426-1447.

DiPaola R, Stein M, Goodin S, Eddy S, Rubin E, Doyle-Indrud S, Dvorzhinski D, Beers S, Shih WJ, White E. Warburg science goes to the bedside: A phase I trial of 2-deoxyglucose in patients with prostate cancer and advanced malignancies. (2008) ASCO meeting Abstracts, 26: 16087

M. N. Stein, B. Knox, E. Wesolowsky, R. Moss, E. Poplin, M. Gounder, S. Gaddam, C. Thomas, S. Goodin, R. DiPaola.  (2009) Phase I trial of patupilone (P) and RAD001 (R) in patients (pts) with advanced solid tumors.  J Clin Onc meeting abstracts.

R. S. DiPaola, Y. Chen, G. J. Bubley, N. M. Hahn, M. Stein, J. Schlom, J. L. Gulley, E. Lattime, M. Carducci, G. Wilding (2009) R. S. DiPaola, Y. Chen, G. J. Bubley, N. M. Hahn, M. Stein, J. Schlom, J. L. Gulley, E. Lattime, M. Carducci, G. Wilding.  ASCO GU meeting poster 2009.

Parikh R, Housman D, Yang Q, Toppmeyer D, Wilson L, Haffty, B.  Prognostic value of Triple-Negative (TN) Phenotype at the time of locally recurrent, conservatively treated breast cancer. International Journal of Radiation Oncology, Biology, Physics, 2008  Nov 15;72(4):1056-6.

Tan A, Toppmeyer D.  Ixabepilone in metastatic breast cancer: Complement or alternative to taxanes? Clinical Cancer Research, 2008 Nov 1;14(21):6725-9.

Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D, Bertino JR.  Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.  Clin Cancer Res. 2009 15(4):1232-40.

Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y.  miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol. 2009 37(2):245-55.

Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin HC, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia. Clin Cancer Res. 2008 14(22):7564-8.

Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008 76(5):582-8.

Medina DJ, Gharibo M, Savage P, Cohler A, Kuriyan M, Balsara B, Anand M, Schaar D, Krimmel T, Saggiomo K, Manago J, Talty L, Dudek L, Grospe S, Rubin A, Strair RK.A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies.  Leuk Res. 2008 32(12):1842-8.

Yip D, Le M, Chan J-L, Lee JH, Mehnert JM, Yudd A, Kempf JS, Shih WJ, Chen S, and Goydos JS. A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma. 2009, Clin Cancer Res 2009 Jun 1;15(11):3896-902.

August DA1, Serrano D1, Poplin E2.  1Division of Surgical Oncology, Department of Surgery, UMDNJ/Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 2Division of Medical Oncology, Department of Medicine, UMDNJ/Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey. ‘‘Spontaneous,’’ Delayed Colon and Rectal Anastomotic Complications Associated With Bevacizumab Therapy.  Journal of Surgical Oncology 2008; 97:180–185.

Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-95.

Hu, G, Yang, Q, Chong, R, Li, F, Blanco, MA, Reiss, M, Haffty, B, and Kang, Y. Genomic Gain of 8q22 Activates Metadherin and Promotes Chemoresistant Metastasis of Poor-Prognosis Breast Cancer. Cancer Cell. 2009 Jan 6;15(1):9-20.

Lu X, Wang Q, Hu G, Van Poznak, C., Fleisher, M., Reiss, M., Massague, J., and Kang, Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & Dev 2009; 23: Published online 7/15/2009.

Saraiya, B., Bodnar-Deren, S., Leventhal, EA, Leventhal H., End of Life Planning and its relevance for patients and oncologists’ decision in choosing cancer therapy, Cancer. 2008 Dec 15; 113(12 Suppl):3540-7.

Saraiya, B.  Oncologists and end-of-life care Journal of Palliative Medicine 2009 February; 12(2):116.

Saraiya, B., Gounder, M., Dutta, J., Saleem, A., Rajendra, R., Collazo, C., Zimmerman, L., Nazar, A., Gharibo, M., Schaar, D., Lin, Y., Shih, W., Aisner, J., Strair, R.K., and Rubin, E. H. (2008)  Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.  Anti-Cancer Drugs 19(4): 411-420.

Medina DJ, Gharibo, M, Savage P, Cohler A, Kuriyan M, Balsara B, Anand M, Schaar D, Krimmel T, Saggiomo K, Manago J, Talty, L, Dudek L, Grospe S, Rubin A, Strair RK.  (2008)  A Pilot Study of Allogeneic Cellular Therapy for Patients with Advanced Hematologic Malignancies. Leukemia Research 32(12): 1842-1848.

Strair RK, Gharibo M, Schaar D, Rubin A, Harrison J, Aisner J, Lin H-S, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ. (2008)  Nuclear Factor-kappaB (NF-kB) modulation in patients undergoing induction chemotherapy for Acute Myelogenous Leukemia.  Clinical Cancer Research. 14(22): 7564-8.

Schaar, Dale G., Medina, Daniel J., Moore, Dirk F., Strair, Roger K. and Ting, Yi. (2009) miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation.  Exp. Hematology. 37(2): 245-55.

Medina DJ, Gharibo, M, Savage, P., Cohler A, Kuriyan M, Balsara B, Anand M, Schaar D, Krimmel T, Saggiomo K, Manago J, Talty L, Dudek L, Grospe S, Rubin A, Strair RK.  A Pilot Study of Allogeneic Cellular Therapy for Patients with Advanced Hematologic Malignancies.  Leukemia Research.  32 (2008) 1842-1848.

Strair RK, Gharibo M, Schaar D, Rubin QA, Harrison J, Aisner J, Lin H-S, Lin Y, Goodell L, Anand M, Balsara B, Dudek L, Rabson A, Medina DJ.  Nuclear Factor-kappaB (NFkB) modulation in patients undergoing induction chemotherapy for Acute Myelogenous Leukemia.  Clinical Cancer Research. 2008. 14(22):7564-8.

Schaar, Dale G., Medina, Daniel J., Moore, Dirk F., Strair, Roger K., and Ting, Yi.  miR-320 targets transferrin Receptor 1 (CD71) and inhibits cell proliferation. Exp. Hematology (2009).

Fetterly G.J., Grasela T.H., Sherman J.W., Dul J.L., Grahn A., Lecomte D., Fiedler-Kelly J., Damjanov N., Fishman M., Kane M.P., Rubin E. H., Tan A.R., Pharmacokinetic and pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome entrapped paclitaxel.  Clin Cancer Res 2008; 14:5856-5863.

Vadhat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., Wright J., Tan A.R., DaCosta N.A., Chuang E., Shuster D.E., Menses N.L., Chandrawansa K., Fang F., Cole P.E., Ashworth S., and Blum J.L.  A phase II study of eribulin mesylate (E7389), a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27: 2954-2961.

Tan A.R., Rubin E.H., Vamos D.C., Shuster D.E., Wong N.Y., Fang F., Ashworth S., and Rosen L.S. A phase I dose-finding study of eribulin mesylate (E7389) administered once every 21 Days in patients with advanced solid tumors.  Clin Cancer Res 2009; 15: 4213-4219.

Tan, A.R., Alexe, G., and Reiss, M.R.  Transforming growth factor-b signaling:  emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-495.

Tan A.R. and Toppmeyer D.L.  Ixabepilone in metastatic breast cancer:  complement or alternative to taxanes?  Clinical Cancer Res 2008; 14: 6725-6729.

Tan A.R. and Swain S.M.  Therapeutic strategies for triple-negative breast cancer.  Cancer J 2008; 14: 343-351.

Wasserman EJ and Tan AR.  Evolving Strategies for the Treatment of "Triple Negative" Breast Cancer, American Society of Clinical Oncology, Educational Book, 2008.

 

Publications Archive
Click Here to browse the Publications Archive